Summary

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models. These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

https://mnmimg.marketsandmarkets.com/Images/drug-discovery-technologies-market-img-overview.webp

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period.
The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.
The oncology segment holds the largest share of the market.
The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.
The US is expected to grow at the highest CAGR during the forecast period.
The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America’s leading position globally.
The primary interviews conducted for this report can be categorized as follows:

? By Respondent: Supply Side ? 70% and Demand Side? 30%
? By Designation: Managers ? 45%, CXOs and Directors ? 30%, and Executives ? 25%
? By Region: North America ? 40%, Europe ? 25%, Asia Pacific ? 25%, Latin America ? 5%, the Middle East & Africa ? 5%
Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOM?RIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schr?dinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolvelT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products.

Research Coverage
This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).
The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
? Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth
? Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market
? Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
? Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market
? Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schr?dinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 42
1.3 STUDY SCOPE 42
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 43
1.3.2 INCLUSIONS AND EXCLUSIONS 44
1.3.3 YEARS CONSIDERED 44
1.4 CURRENCY CONSIDERED 45
1.5 STAKEHOLDERS 45
1.6 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 47
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 47
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 48
2.3 DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET 49
2.4 HIGH-GROWTH SEGMENTS 50
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 51
3 PREMIUM INSIGHTS 53
3.1 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 53
3.2 DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
3.3 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%) 55
4 MARKET OVERVIEW 56
4.1 INTRODUCTION 56
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 57
4.2.1.1 Increasing adoption of advanced screening platforms 57
4.2.1.2 Shift toward biologics and advanced therapeutic modalities 58
4.2.1.3 Transition from conventional two-dimensional cultures to three-dimensional models 58
4.2.1.4 Technological innovations in assay miniaturization and automation 59
4.2.2 RESTRAINTS 59
4.2.2.1 High up-front investment in instruments, automation,
and data infrastructure 59
4.2.2.2 Shortage of skilled personnel 60
4.2.3 OPPORTUNITIES 60
4.2.3.1 Growing demand for in-silico-based discovery 60
4.2.3.2 Increasing need for specialized ADME/Toxicology testing 60
4.2.4 CHALLENGES 61
4.2.4.1 Assay reproducibility and standardization issues 61
4.3 UNMET NEEDS AND WHITE SPACES 61
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 62
5 INDUSTRY TRENDS 64
5.1 PORTER’S FIVE FORCES ANALYSIS 64
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 65
5.1.2 BARGAINING POWER OF SUPPLIERS 65
5.1.3 BARGAINING POWER OF BUYERS 66
5.1.4 THREAT OF SUBSTITUTES 66
5.1.5 THREAT OF NEW ENTRANTS 66
5.2 MACROECONOMIC OUTLOOK 66
5.2.1 INTRODUCTION 66
5.2.2 GDP TRENDS AND FORECAST 66
5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 67
5.2.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 67
5.3 VALUE CHAIN ANALYSIS 68
5.4 ECOSYSTEM ANALYSIS 69
5.5 PRICING ANALYSIS 71
5.5.1 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024 71
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022?2024 71
5.5.2.1 Average selling price of instruments, by key player, 2024 72
5.5.2.2 Average selling price of consumables, by key player, 2024 73
5.5.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022?2024 73
5.5.4 AVERAGE SELLING PRICE TREND, BY REGION, 2022?2024 74
5.6 TRADE ANALYSIS 75
5.6.1 IMPORT SCENARIO FOR HS CODE 3822.00 76
5.6.2 EXPORT SCENARIO FOR HS CODE 3822.00 76
5.6.3 IMPORT SCENARIO FOR HS CODE 9027.00 77
5.6.4 EXPORT SCENARIO FOR HS CODE 9027.00 78
5.7 KEY CONFERENCES AND EVENTS, 2025?2026 79
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.9 INVESTMENT AND FUNDING SCENARIO 80
5.10 CASE STUDY ANALYSIS 81
5.10.1 AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT 81
5.10.2 INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY 82
5.10.3 NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN 82
?
5.11 IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET 82
5.11.1 INTRODUCTION 82
5.11.2 KEY TARIFF RATES 82
5.11.3 PRICE IMPACT ANALYSIS 86
5.11.4 KEY IMPACT ON COUNTRIES/REGIONS 86
5.11.4.1 US 86
5.11.4.2 Europe 87
5.11.4.3 Asia Pacific 87
5.11.5 END-USE INDUSTRY IMPACT 87
5.11.5.1 Pharmaceutical and Biotechnology Companies 87
5.11.5.2 Academic and Research Institutes 88
5.11.5.3 Contract Research Organizations (CROs) 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 KEY EMERGING TECHNOLOGIES 89
6.1.1 HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION 89
6.1.2 AUTOMATED LIQUID HANDLING 89
6.2 ADJACENT TECHNOLOGIES 90
6.2.1 AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS 90
6.2.2 DISCOVERY INFORMATICS & LAB DIGITALIZATION 90
6.3 TECHNOLOGY/PRODUCT ROADMAP 91
6.4 PATENT ANALYSIS 91
6.4.1 METHODOLOGY 91
6.4.2 NUMBER OF PATENTS FILED 91
6.4.3 LIST OF KEY PATENTS 93
6.5 FUTURE APPLICATIONS 94
6.6 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET 94
6.6.1 TOP USE CASES AND MARKET POTENTIAL 95
6.6.2 BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS 96
6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY
TECHNOLOGIES MARKET 96
6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 96
6.6.5 CLIENTS’ READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN
IN DRUG DISCOVERY TECHNOLOGIES MARKET 97
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 98
7.1 REGIONAL REGULATIONS AND COMPLIANCE 98
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
7.1.2 INDUSTRY STANDARDS 100
7.1.2.1 North America 101
7.1.2.1.1 US 101
7.1.2.1.2 Canada 101
7.1.2.2 Europe 101
7.1.2.2.1 UK 102
7.1.2.3 Asia Pacific 102
7.1.2.3.1 China 102
7.1.2.3.2 Japan 103
7.1.2.3.3 India 103
7.1.2.3.4 South Korea 103
7.1.2.3.5 Australia 104
7.1.2.3.6 Rest of Asia Pacific 104
7.2 SUSTAINABILITY INITIATIVES 104
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 105
7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS 105
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 107
8.1 DECISION-MAKING PROCESS 107
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 107
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
8.2.2 KEY BUYING CRITERIA, BY END USER 108
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 109
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109
9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 111
9.1 INTRODUCTION 112
9.2 REAGENTS & CONSUMABLES 112
9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH 112
9.3 INSTRUMENTS 116
9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET 116
9.4 BIOINFORMATICS TOOLS & SOFTWARE 119
9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET 119
10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY 123
10.1 INTRODUCTION 124
10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES 124
10.2.1 AUTOMATED LIQUID HANDLING 128
10.2.1.1 Increasing focus on precision, integration, and productivity to drive market 128
10.2.2 MICROPLATE-BASED HTS 132
10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D
to fuel market 132
10.2.3 LAB-ON-A CHIP 135
10.2.3.1 Increasing demand for more predictive preclinical models to boost market 135
10.2.4 LABEL-FREE TECHNOLOGY 139
10.2.4.1 Real-time, label-free interaction to accelerate segment growth 139
10.3 NEXT-GENERATION SEQUENCING 142
10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET 142
10.4 POLYMERASE CHAIN REACTION 146
10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET 146
10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES 149
10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET 149
10.6 X-RAY CRYSTALLOGRAPHY 152
10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET 152
10.7 CHROMATOGRAPHY 156
10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH 156
10.8 MASS SPECTROMETRY 159
10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET 159
10.9 OTHER TECHNOLOGIES 163
11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS 167
11.1 INTRODUCTION 168
11.2 TARGET IDENTIFICATION 168
11.2.1 INCREASING CLINICAL DATA VOLUME TO BOOST MARKET 168
11.3 TARGET VALIDATION 172
11.3.1 INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH 172
11.4 HIT-TO-LEAD IDENTIFICATION 175
11.4.1 GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET 175
11.5 LEAD OPTIMIZATION 179
11.5.1 INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET 179
11.6 CANDIDATE VALIDATION 182
11.6.1 INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH 182
12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA 186
12.1 INTRODUCTION 187
12.2 ONCOLOGY 187
12.2.1 SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH 187
?
12.3 INFECTIOUS DISEASES 191
12.3.1 RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET 191
12.4 CARDIOVASCULAR DISEASES 194
12.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET 194
12.5 NEUROLOGICAL DISEASES 198
12.5.1 INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET 198
12.6 ENDOCRINE & METABOLIC DISORDERS 201
12.6.1 RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET 201
12.7 AUTOIMMUNE DISORDERS 205
12.7.1 WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET 205
12.8 OTHER THERAPEUTIC AREAS 208
13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER 212
13.1 INTRODUCTION 213
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 213
13.2.1 TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRBUTE TO GROWTH 213
13.3 ACADEMIC & RESEARCH INSTITUTES 217
13.3.1 RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC?INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH 217
13.4 CONTRACT RESEARCH ORGANIZATIONS (CROS) 220
13.4.1 INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH 220
14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION 224
14.1 INTRODUCTION 225
14.2 NORTH AMERICA 225
14.2.1 US 230
14.2.1.1 Expanding network of cross-border partnerships and investments to expedite growth 230
14.2.2 CANADA 233
14.2.2.1 Increasing adoption of AI and open-science models to accelerate growth 233
14.3 EUROPE 237
14.3.1 GERMANY 241
14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market 241
14.3.2 UK 244
14.3.2.1 Increasing focus on next-generation computational platforms to promote growth 244
14.3.3 FRANCE 248
14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market 248
14.3.4 ITALY 251
14.3.4.1 Rising research funding to contribute to growth 251
14.3.5 SPAIN 255
14.3.5.1 Well-established network of research centers and universities to boost market 255
14.3.6 REST OF EUROPE 258
14.4 ASIA PACIFIC 262
14.4.1 CHINA 266
14.4.1.1 Global partnerships to propel market 266
14.4.2 JAPAN 270
14.4.2.1 Rising integration of AI and international partnerships to favor growth 270
14.4.3 INDIA 273
14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth 273
14.4.4 AUSTRALIA 277
14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth 277
14.4.5 SOUTH KOREA 280
14.4.5.1 Favorable public policies to support growth 280
14.4.6 REST OF ASIA PACIFIC 284
14.5 LATIN AMERICA 287
14.5.1 BRAZIL 291
14.5.1.1 Public-private collaborations to bolster growth 291
14.5.2 MEXICO 295
14.5.2.1 Rising demand for AI-powered research to support growth 295
14.5.3 REST OF LATIN AMERICA 298
14.6 MIDDLE EAST 302
14.6.1 GCC COUNTRIES 305
14.6.1.1 Saudi Arabia 309
14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market 309
14.6.1.2 UAE 312
14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth 312
14.6.1.3 Rest of GCC countries 316
14.6.2 REST OF MIDDLE EAST 319
14.7 AFRICA 323
14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET 323
?
15 COMPETITIVE LANDSCAPE 327
15.1 OVERVIEW 327
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN 327
15.3 REVENUE ANALYSIS 329
15.4 MARKET SHARE ANALYSIS 329
15.5 BRAND/PRODUCT COMPARISON 332
15.5.1 THERMO FISHER SCIENTIFIC INC. 333
15.5.2 MERCK KGAA 333
15.5.3 AGILENT TECHNOLOGIES, INC. 333
15.5.4 REVVITY 333
15.5.5 ILLUMINA, INC. 333
15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 333
15.6.1 STARS 334
15.6.2 EMERGING LEADERS 334
15.6.3 PERVASIVE PLAYERS 334
15.6.4 PARTICIPANTS 334
15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 336
15.6.5.1 Company footprint 336
15.6.5.2 Region footprint 337
15.6.5.3 Product footprint 338
15.6.5.4 Technology footprint 339
15.6.5.5 Process footprint 340
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 341
15.7.1 PROGRESSIVE COMPANIES 341
15.7.2 RESPONSIVE COMPANIES 341
15.7.3 DYNAMIC COMPANIES 341
15.7.4 STARTING BLOCKS 341
15.7.5 COMPETITIVE BENCHMARKING 343
15.7.5.1 Detailed list of key startups/SMEs 343
15.7.5.2 Competitive benchmarking of key startups/SMEs 344
15.8 COMPANY VALUATION AND FINANCIAL METRICS 345
15.9 COMPETITIVE SCENARIO 346
15.9.1 PRODUCT LAUNCHES 346
15.9.2 DEALS 347
15.9.3 EXPANSIONS 348
15.9.4 OTHER DEVELOPMENTS 348
16 COMPANY PROFILES 349
16.1 KEY PLAYERS 349
16.1.1 THERMO FISHER SCIENTIFIC INC. 349
16.1.1.1 Business overview 349
16.1.1.2 Products offered 350
16.1.1.3 Recent developments 353
16.1.1.3.1 Product launches 353
16.1.1.3.2 Deals 354
16.1.1.3.3 Expansions 354
16.1.1.4 MnM view 354
16.1.1.4.1 Key strengths/Right to win 354
16.1.1.4.2 Strategic choices 355
16.1.1.4.3 Weaknesses/Competitive threats 355
16.1.2 MERCK KGAA 356
16.1.2.1 Business overview 356
16.1.2.2 Products offered 357
16.1.2.3 Recent developments 358
16.1.2.3.1 Deals 358
16.1.2.3.2 Expansions 359
16.1.2.4 MnM view 359
16.1.2.4.1 Key strengths/Right to win 359
16.1.2.4.2 Strategic choices 359
16.1.2.4.3 Weaknesses/Competitive threats 359
16.1.3 AGILENT TECHNOLOGIES, INC. 360
16.1.3.1 Business overview 360
16.1.3.2 Products offered 361
16.1.3.3 Recent developments 363
16.1.3.3.1 Product launches 363
16.1.3.3.2 Expansions 364
16.1.3.4 MnM view 364
16.1.3.4.1 Key strengths/Right to win 364
16.1.3.4.2 Strategic choices 364
16.1.3.4.3 Weaknesses/Competitive threats 364
16.1.4 REVVITY 365
16.1.4.1 Business overview 365
16.1.4.2 Products offered 366
16.1.4.3 Recent developments 368
16.1.4.3.1 Product launches 368
16.1.4.3.2 Deals 368
16.1.4.3.3 Expansions 368
16.1.4.4 MnM view 369
16.1.4.4.1 Key strengths/Right to win 369
16.1.4.4.2 Strategic choices 369
16.1.4.4.3 Weaknesses/Competitive threats 369
?
16.1.5 ILLUMINA, INC. 370
16.1.5.1 Business overview 370
16.1.5.2 Products offered 371
16.1.5.3 Recent developments 372
16.1.5.3.1 Product launches 372
16.1.5.3.2 Deals 373
16.1.5.3.3 Expansions 373
16.1.5.3.4 Other developments 374
16.1.5.4 MnM view 374
16.1.5.4.1 Key strengths/Right to win 374
16.1.5.4.2 Strategic choices 374
16.1.5.4.3 Weaknesses/Competitive threats 374
16.1.6 DANAHER CORPORATION 375
16.1.6.1 Business overview 375
16.1.6.2 Products offered 376
16.1.6.3 Recent developments 380
16.1.6.3.1 Product launches 380
16.1.6.3.2 Deals 380
16.1.6.3.3 Expansions 381
16.1.6.4 MnM view 381
16.1.6.4.1 Key strengths/Right to win 381
16.1.6.4.2 Strategic choices 381
16.1.6.4.3 Weaknesses/Competitive threats 381
16.1.7 F. HOFFMANN-LA ROCHE LTD 382
16.1.7.1 Business overview 382
16.1.7.2 Products offered 383
16.1.7.3 Recent developments 385
16.1.7.3.1 Product launches 385
16.1.7.3.2 Deals 385
16.1.7.3.3 Other developments 385
16.1.8 BRUKER 386
16.1.8.1 Business overview 386
16.1.8.2 Products offered 387
16.1.8.3 Recent developments 388
16.1.8.3.1 Product launches 388
16.1.8.3.2 Deals 389
16.1.8.3.3 Expansions 389
16.1.9 QIAGEN 390
16.1.9.1 Business overview 390
16.1.9.2 Products offered 391
16.1.9.3 Recent developments 392
16.1.9.3.1 Product launches 392
16.1.9.3.2 Deals 393
16.1.9.3.3 Expansions 393
16.1.10 BIO-RAD LABORATORIES, INC. 394
16.1.10.1 Business overview 394
16.1.10.2 Products offered 395
16.1.10.3 Recent developments 397
16.1.10.3.1 Product launches 397
16.1.10.3.2 Deals 397
16.1.11 TECAN TRADING AG 398
16.1.11.1 Business overview 398
16.1.11.2 Products offered 400
16.1.12 TAKARA BIO INC. 401
16.1.12.1 Business overview 401
16.1.12.2 Products offered 402
16.1.12.3 Recent developments 403
16.1.12.3.1 Product launches 403
16.1.13 CORNING INCORPORATED 404
16.1.13.1 Business overview 404
16.1.13.2 Products offered 406
16.1.14 HAMILTON COMPANY 407
16.1.14.1 Business overview 407
16.1.14.2 Products offered 407
16.1.14.3 Recent developments 408
16.1.14.3.1 Product launches 408
16.1.14.3.2 Deals 408
16.1.15 PACBIO 409
16.1.15.1 Business overview 409
16.1.15.2 Products offered 410
16.1.15.3 Recent developments 412
16.1.15.3.1 Product launches 412
16.1.15.3.2 Expansions 412
16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC 413
16.1.16.1 Business overview 413
16.1.16.2 Products offered 415
16.1.16.3 Recent developments 416
16.1.16.3.1 Product launches 416
16.1.16.3.2 Deals 416
16.1.17 PROMEGA CORPORATION 417
16.1.17.1 Business overview 417
16.1.17.2 Products offered 418
?
16.1.18 WATERS CORPORATION 419
16.1.18.1 Business overview 419
16.1.18.2 Products offered 421
16.1.18.3 Recent developments 422
16.1.18.3.1 Product launches 422
16.1.18.3.2 Deals 422
16.1.19 SARTORIUS AG 423
16.1.19.1 Business overview 423
16.1.19.2 Products offered 425
16.1.19.3 Recent developments 426
16.1.19.3.1 Deals 426
16.1.20 BD 427
16.1.20.1 Business overview 427
16.1.20.2 Products offered 428
16.1.20.3 Recent developments 429
16.1.20.3.1 Product launches 429
16.1.20.3.2 Deals 430
16.1.21 EPPENDORF SE 431
16.1.21.1 Business overview 431
16.1.21.2 Products offered 433
16.1.21.3 Recent developments 434
16.1.21.3.1 Deals 434
16.1.22 SHIMADZU CORPORATION 435
16.1.22.1 Business overview 435
16.1.22.2 Business overview 435
16.1.22.3 Products offered 436
16.1.23 AURORA BIOMED INC. 438
16.1.23.1 Business overview 438
16.1.23.2 Products offered 438
16.1.24 STANDARD BIOTOOLS 439
16.1.24.1 Business overview 439
16.1.24.2 Products offered 440
16.1.25 JEOL LTD. 441
16.1.25.1 Business overview 441
16.1.25.2 Products offered 443
16.1.26 GILSON INCORPORATED 444
16.1.26.1 Business overview 444
16.1.26.2 Products offered 444
16.1.27 BIOM?RIEUX 445
16.1.27.1 Business overview 445
16.1.27.2 Products offered 446
?
16.1.28 GREINER AG 447
16.1.28.1 Business overview 447
16.1.28.2 Products offered 448
16.1.29 BGI GROUP 449
16.1.29.1 Business overview 449
16.1.29.2 Products offered 449
16.1.30 PORVAIR 451
16.1.30.1 Business overview 451
16.1.30.2 Products offered 452
16.2 OTHER PLAYERS 453
16.2.1 POLARIS GENOMICS 453
16.2.2 BICO 454
16.2.3 CREATIVE BIOARRAY 455
16.2.4 SPHERE BIO 455
16.2.5 GENSCRIPT 456
16.2.6 SCHR?DINGER, INC. 457
16.2.7 LECO CORPORATION 458
16.2.8 TRANSGEN BIOTECH CO., LTD 459
16.2.9 BMG LABTECH 460
16.2.10 NANOTEMPER TECHNOLOGIES 461
16.2.11 MGI TECH CO., LTD. 462
16.2.12 ARACELI BIOSCIENCES 463
16.2.13 ANALYTIK JENA GMBH+CO. KG 464
16.2.14 BIOSOLVEIT GMBH 465
16.2.15 EVOSEP 466
17 RESEARCH METHODOLOGY 467
17.1 RESEARCH DATA 467
17.1.1 SECONDARY DATA 468
17.1.1.1 Key data from secondary sources 468
17.1.2 PRIMARY DATA 469
17.1.2.1 Key data from primary sources 469
17.1.2.2 Key primary participants 469
17.1.2.3 Breakdown of primary interviews 470
17.1.2.4 Key industry insights 471
17.2 MARKET SIZE ESTIMATION 472
17.2.1 BOTTOM-UP APPROACH 472
17.2.2 TOP-DOWN APPROACH 474
17.2.3 BASE NUMBER CALCULATION 475
17.3 GROWTH FORECAST MODEL 476
17.4 DATA TRIANGULATION 477
17.5 FACTOR ANALYSIS 478
17.6 RESEARCH ASSUMPTIONS 478
17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 479
18 APPENDIX 481
18.1 DISCUSSION GUIDE 481
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 485
18.3 CUSTOMIZATION OPTIONS 487
18.4 RELATED REPORTS 487
18.5 AUTHOR DETAILS 488

ページTOPに戻る

List of Tables/Graphs

TABLE 1 DRUG DISCOVERY TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS 44
TABLE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: IMPACT ANALYSIS
OF MARKET DYNAMICS 57
TABLE 3 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES 64
TABLE 4 DRUG DISCOVERY TECHNOLOGIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70
TABLE 5 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYERS, 2024 71
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022?2024 (USD MILLION) 71
TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022?2024 73
TABLE 8 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION,
2022?2024 (USD MILLION) 74
TABLE 9 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION,
2022?2024 (USD MILLION) 74
TABLE 10 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY,
2020?2024 (USD THOUSAND) 76
TABLE 11 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY,
2020?2024 (USD THOUSAND) 76
TABLE 12 IMPORT DATA FOR HS CODE 9027.00, BY COUNTRY,
2020?2024 (USD THOUSAND) 77
TABLE 13 EXPORT DATA FOR HS CODE 9027.00, BY COUNTRY,
2020?2024 (USD THOUSAND) 78
TABLE 14 DRUG DISCOVERY TECHNOLOGIES MARKET: KEY CONFERENCES AND
EVENTS, 2025?2026 79
TABLE 15 US ADJUSTED RECIPROCAL TARIFF RATES 82
TABLE 16 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO DRUG DISCOVERY TECHNOLOGIES 85
TABLE 17 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 86
TABLE 18 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014?2024 91
TABLE 19 LIST OF KEY PATENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2023?2025 93
TABLE 20 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY
TECHNOLOGIES MARKET 96
TABLE 21 CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET 97
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 98
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 98
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 99
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 100
TABLE 26 DRUG DISCOVERY TECHNOLOGIES MARKET: VENDOR CERTIFICATIONS 106
TABLE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 108
TABLE 28 KEY BUYING CRITERIA, BY END USER 108
TABLE 29 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 112
TABLE 30 DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES,
BY REGION, 2023?2030 (USD MILLION) 113
TABLE 31 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023?2030 (USD MILLION) 113
TABLE 32 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023?2030 (USD MILLION) 114
TABLE 33 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023?2030 (USD MILLION) 114
TABLE 34 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023?2030 (USD MILLION) 115
TABLE 35 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023?2030 (USD MILLION) 115
TABLE 36 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023?2030 (USD MILLION) 115
TABLE 37 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023?2030 (USD MILLION) 116
TABLE 38 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023?2030 (USD MILLION) 117
TABLE 39 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023?2030 (USD MILLION) 117
TABLE 40 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023?2030 (USD MILLION) 118
TABLE 41 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023?2030 (USD MILLION) 118
TABLE 42 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS,
BY REGION, 2023?2030 (USD MILLION) 119
TABLE 43 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023?2030 (USD MILLION) 119
TABLE 44 DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023?2030 (USD MILLION) 120
TABLE 45 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023?2030 (USD MILLION) 120
TABLE 46 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023?2030 (USD MILLION) 121
TABLE 47 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023?2030 (USD MILLION) 121
TABLE 48 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023?2030 (USD MILLION) 122
TABLE 49 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023?2030 (USD MILLION) 122
TABLE 50 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023?2030 (USD MILLION) 122
TABLE 51 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023?2030 (USD MILLION) 124
TABLE 52 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY TYPE, 2023?2030 (USD MILLION) 125
TABLE 53 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023?2030 (USD MILLION) 125
TABLE 54 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 126
TABLE 55 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 126
TABLE 56 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 127
TABLE 57 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 127
TABLE 58 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION,
2023?2030 (USD MILLION) 128
TABLE 59 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 128
TABLE 60 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023?2030 (USD MILLION) 129
TABLE 61 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 129
TABLE 62 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 130
TABLE 63 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 130
TABLE 64 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 131
TABLE 65 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023?2030 (USD MILLION) 131
TABLE 66 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023?2030 (USD MILLION) 131
TABLE 67 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS,
BY REGION, 2023?2030 (USD MILLION) 132
TABLE 68 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023?2030 (USD MILLION) 133
TABLE 69 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023?2030 (USD MILLION) 133
TABLE 70 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE- BASED HTS, BY COUNTRY, 2023?2030 (USD MILLION) 134
TABLE 71 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE-BASED HTS, BY COUNTRY, 2023?2030 (USD MILLION) 134
TABLE 72 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE-BASED HTS, BY REGION, 2023?2030 (USD MILLION) 135
TABLE 73 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE-BASED HTS, BY COUNTRY, 2023?2030 (USD MILLION) 135
TABLE 74 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY REGION, 2023?2030 (USD MILLION) 136
TABLE 75 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LAB-ON-A CHIP, BY COUNTRY, 2023?2030 (USD MILLION) 136
TABLE 76 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY COUNTRY, 2023?2030 (USD MILLION) 137
TABLE 77 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY COUNTRY, 2023?2030 (USD MILLION) 137
TABLE 78 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023?2030 (USD MILLION) 138
TABLE 79 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY REGION, 2023?2030 (USD MILLION) 138
TABLE 80 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LAB-ON-A CHIP, BY COUNTRY, 2023?2030 (USD MILLION) 138
TABLE 81 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY,
BY REGION, 2023?2030 (USD MILLION) 139
TABLE 82 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023?2030 (USD MILLION) 140
TABLE 83 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023?2030 (USD MILLION) 140
TABLE 84 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023?2030 (USD MILLION) 141
TABLE 85 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023?2030 (USD MILLION) 141
TABLE 86 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023?2030 (USD MILLION) 142
TABLE 87 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023?2030 (USD MILLION) 142
TABLE 88 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023?2030 (USD MILLION) 143
TABLE 89 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023?2030 (USD MILLION) 143
TABLE 90 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023?2030 (USD MILLION) 144
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023?2030 (USD MILLION) 144
TABLE 92 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023?2030 (USD MILLION) 145
TABLE 93 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023?2030 (USD MILLION) 145
TABLE 94 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023?2030 (USD MILLION) 145
TABLE 95 DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023?2030 (USD MILLION) 146
TABLE 96 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023?2030 (USD MILLION) 147
TABLE 97 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023?2030 (USD MILLION) 147
TABLE 98 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023?2030 (USD MILLION) 148
TABLE 99 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023?2030 (USD MILLION) 148
TABLE 100 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023?2030 (USD MILLION) 149
TABLE 101 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023?2030 (USD MILLION) 149
TABLE 102 DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2023?2030 (USD MILLION) 150
TABLE 103 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 150
TABLE 104 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 151
TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 151
TABLE 106 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 152
TABLE 107 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023?2030 (USD MILLION) 152
TABLE 108 DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY,
BY REGION, 2023?2030 (USD MILLION) 153
TABLE 109 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 153
TABLE 110 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 154
TABLE 111 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 154
TABLE 112 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 155
TABLE 113 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023?2030 (USD MILLION) 155
TABLE 114 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 155
TABLE 115 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY,
BY REGION, 2023?2030 (USD MILLION) 156
TABLE 116 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 157
TABLE 117 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2023?2030 (USD MILLION) 157
TABLE 118 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 158
TABLE 119 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 158
TABLE 120 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023?2030 (USD MILLION) 159
TABLE 121 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023?2030 (USD MILLION) 159
TABLE 122 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY,
BY REGION, 2023?2030 (USD MILLION) 160
TABLE 123 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023?2030 (USD MILLION) 160
TABLE 124 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MASS SPECTROMETRY, BY COUNTRY, 2023?2030 (USD MILLION) 161
TABLE 125 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023?2030 (USD MILLION) 161
TABLE 126 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023?2030 (USD MILLION) 162
TABLE 127 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023?2030 (USD MILLION) 162
TABLE 128 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023?2030 (USD MILLION) 162
TABLE 129 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2023?2030 (USD MILLION) 163
TABLE 130 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 164
TABLE 131 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 164
TABLE 132 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 165
TABLE 133 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 165
TABLE 134 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR OTHER TECHNOLOGIES, BY REGION, 2023?2030 (USD MILLION) 166
TABLE 135 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023?2030 (USD MILLION) 166
TABLE 136 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 168
TABLE 137 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION,
BY REGION, 2023?2030 (USD MILLION) 169
TABLE 138 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 169
TABLE 139 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 170
TABLE 140 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 170
TABLE 141 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 171
TABLE 142 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023?2030 (USD MILLION) 171
TABLE 143 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 171
TABLE 144 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,
BY REGION, 2023?2030 (USD MILLION) 172
TABLE 145 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 173
TABLE 146 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,
BY COUNTRY, 2023?2030 (USD MILLION) 173
TABLE 147 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 174
TABLE 148 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 174
TABLE 149 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023?2030 (USD MILLION) 175
TABLE 150 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,BY COUNTRY, 2023?2030 (USD MILLION) 175
TABLE 151 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION,
BY REGION, 2023?2030 (USD MILLION) 176
TABLE 152 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 176
TABLE 153 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 177
TABLE 154 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 177
TABLE 155 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 178
TABLE 156 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023?2030 (USD MILLION) 178
TABLE 157 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023?2030 (USD MILLION) 178
TABLE 158 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION,
BY REGION, 2023?2030 (USD MILLION) 179
TABLE 159 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023?2030 (USD MILLION) 180
TABLE 160 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION,
BY COUNTRY, 2023?2030 (USD MILLION) 180
TABLE 161 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023?2030 (USD MILLION) 181
TABLE 162 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023?2030 (USD MILLION) 181
TABLE 163 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023?2030 (USD MILLION) 182
TABLE 164 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023?2030 (USD MILLION) 182
TABLE 165 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION,
BY REGION, 2023?2030 (USD MILLION) 183
TABLE 166 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 183
TABLE 167 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 184
TABLE 168 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 184
TABLE 169 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 185
TABLE 170 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023?2030 (USD MILLION) 185
TABLE 171 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023?2030 (USD MILLION) 185
TABLE 172 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023?2030 (USD MILLION) 187
TABLE 173 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION,
2023?2030 (USD MILLION) 188
TABLE 174 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023?2030 (USD MILLION) 188
TABLE 175 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023?2030 (USD MILLION) 189
TABLE 176 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023?2030 (USD MILLION) 189
TABLE 177 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023?2030 (USD MILLION) 190
TABLE 178 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY REGION, 2023?2030 (USD MILLION) 190
TABLE 179 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023?2030 (USD MILLION) 190
TABLE 180 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2023?2030 (USD MILLION) 191
TABLE 181 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 192
TABLE 182 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 192
TABLE 183 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 193
TABLE 184 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 193
TABLE 185 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023?2030 (USD MILLION) 194
TABLE 186 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 194
TABLE 187 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2023?2030 (USD MILLION) 195
TABLE 188 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 195
TABLE 189 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 196
TABLE 190 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 196
TABLE 191 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 197
TABLE 192 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023?2030 (USD MILLION) 197
TABLE 193 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 197
TABLE 194 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES,
BY REGION, 2023?2030 (USD MILLION) 198
TABLE 195 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 199
TABLE 196 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 199
TABLE 197 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 200
TABLE 198 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 200
TABLE 199 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023?2030 (USD MILLION) 201
TABLE 200 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023?2030 (USD MILLION) 201
TABLE 201 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023?2030 (USD MILLION) 202
TABLE 202 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 202
TABLE 203 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 203
TABLE 204 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 203
TABLE 205 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 204
TABLE 206 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023?2030 (USD MILLION) 204
TABLE 207 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 204
TABLE 208 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS,
BY REGION, 2023?2030 (USD MILLION) 205
TABLE 209 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 206
TABLE 210 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 206
TABLE 211 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 207
TABLE 212 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 207
TABLE 213 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023?2030 (USD MILLION) 208
TABLE 214 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023?2030 (USD MILLION) 208
TABLE 215 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2023?2030 (USD MILLION) 209
TABLE 216 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023?2030 (USD MILLION) 209
TABLE 217 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023?2030 (USD MILLION) 210
TABLE 218 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023?2030 (USD MILLION) 210
TABLE 219 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023?2030 (USD MILLION) 211
TABLE 220 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY REGION, 2023?2030 (USD MILLION) 211
TABLE 221 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023?2030 (USD MILLION) 211
TABLE 222 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 213
TABLE 223 DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023?2030 (USD MILLION) 214
TABLE 224 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023?2030 (USD MILLION) 214
TABLE 225 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023?2030 (USD MILLION) 215
TABLE 226 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023?2030 (USD MILLION) 215
TABLE 227 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023?2030 (USD MILLION) 216
TABLE 228 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023?2030 (USD MILLION) 216
TABLE 229 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023?2030 (USD MILLION) 216
TABLE 230 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023?2030 (USD MILLION) 217
TABLE 231 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 218
TABLE 232 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 218
TABLE 233 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 219
TABLE 234 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 219
TABLE 235 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023?2030 (USD MILLION) 220
TABLE 236 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023?2030 (USD MILLION) 220
TABLE 237 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023?2030 (USD MILLION) 221
TABLE 238 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023?2030 (USD MILLION) 221
TABLE 239 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023?2030 (USD MILLION) 222
TABLE 240 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023?2030 (USD MILLION) 222
TABLE 241 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023?2030 (USD MILLION) 223
TABLE 242 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023?2030 (USD MILLION) 223
TABLE 243 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023?2030 (USD MILLION) 223
TABLE 244 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION,
2023?2030 (USD MILLION) 225
TABLE 245 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2023?2030 (USD MILLION) 226
TABLE 246 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2023?2030 (USD MILLION) 227
TABLE 247 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY TECHNOLOGY, 2023?2030 (USD MILLION) 227
TABLE 248 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023?2030 (USD MILLION) 228
TABLE 249 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PROCESS, 2023?2030 (USD MILLION) 228
TABLE 250 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023?2030 (USD MILLION) 229TABLE 251 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023?2030 (USD MILLION) 229
TABLE 252 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 230
TABLE 253 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023?2030 (USD MILLION) 231
TABLE 254 US: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023?2030 (USD MILLION) 231
TABLE 255 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 232
TABLE 256 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023?2030 (USD MILLION) 232
TABLE 257 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 233
TABLE 258 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 234
TABLE 259 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023?2030 (USD MILLION) 234
TABLE 260 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023?2030 (USD MILLION) 235
TABLE 261 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 235
TABLE 262 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023?2030 (USD MILLION) 236
TABLE 263 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 236
TABLE 264 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY,
2023?2030 (USD MILLION) 237
TABLE 265 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 238
TABLE 266 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023?2030 (USD MILLION) 238
TABLE 267 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023?2030 (USD MILLION) 239
TABLE 268 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 239
TABLE 269 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023?2030 (USD MILLION) 240
TABLE 270 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 240
TABLE 271 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 241
TABLE 272 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023?2030 (USD MILLION) 242
TABLE 273 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023?2030 (USD MILLION) 242
TABLE 274 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023?2030 (USD MILLION) 243
TABLE 275 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023?2030 (USD MILLION) 243
TABLE 276 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023?2030 (USD MILLION) 244
TABLE 277 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023?2030 (USD MILLION) 245
TABLE 278 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023?2030 (USD MILLION) 245
TABLE 279 UK: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLO